Related Experiment Videos
[Eosinophil activation markers in status asthmaticus]
Orvosi Hetilap
|January 21, 1996
Summary
In acute severe asthma, eosinophil activation markers like eosinophil cationic protein and eosinophil protein-X were elevated at admission and decreased over eight days. Monitoring these eosinophil markers may aid in optimizing asthma treatment.
Area of Science:
- Pulmonology
- Immunology
- Biochemistry
Background:
- Acute severe asthma is characterized by airway inflammation.
- Eosinophils play a key role in asthma pathogenesis.
- Specific markers indicate eosinophil activation in vivo.
Purpose of the Study:
- To investigate eosinophil activation markers in acute severe asthma.
- To correlate marker levels with disease severity and treatment response.
- To assess the potential clinical utility of monitoring eosinophil activity.
Main Methods:
- Measurement of eosinophil cationic protein (ECP) and eosinophil protein-X (EPX) levels.
- Serial measurements at admission and after eight days.
- Monitoring of peak expiratory flow rates (PEFR).
Main Results:
- Elevated ECP and EPX levels were observed in all patients upon admission.
- A decreasing tendency of ECP and EPX levels was noted after eight days.
- No direct correlation was found between the degree of bronchial obstruction and eosinophil marker levels.
Conclusions:
- Eosinophil activation is confirmed in patients with acute severe asthma.
- Continuous monitoring of eosinophil activity markers may offer practical value for guiding asthma therapy.
- Further research is warranted to establish optimal therapeutic strategies based on eosinophil activity.